When: Confirmed close above $96

Then: Trim additional 10% of position

HOLD with modest allocation; trim trigger above $94; exit trigger below $86.50 on sustained basis

• Current stop at $86.50 provides $4.64 cushion (~2.23 ATR) versus aggressive proposal at $87.50 providing only $3.64 cushion (~1.75 ATR)
• RSI at 59 with five sessions of lower highs after tagging $94.72; MACD peaked at 2.64 on August 21 and has been declining with histogram now at zero
• Price closed below 10 EMA at $91.51 with bearish candle opening at $92.28 and closing near session lows
• 200 SMA at $88.68 was only recently reclaimed after February break; not confirmed uptrend but freshly reclaimed structural level
• TTM EPS $3.73 versus forward consensus $6.40 implies 72% EPS expansion dependent on tax rate normalization to 18-21% range
• January 2026 quarter showed 31.4% effective tax rate; geographic tax exposure could undermine EPS expansion thesis
• Forward P/E of 14.2x could re-price to 22-24x on lower actual earnings, creating derating event to $73-75 zone
• Goodwill and intangibles of $52.73 billion (57% of assets) with negative tangible book value provides no cushion for potential impairment charges
• Q4 FY26 acquisition of $406 million in new business continues M&A appetite and goodwill accumulation
• Dividend at $0.72 quarterly (3.1% yield) is a sentimental marker; 50th consecutive year doesn't change economics
• Polymarket shows 86% probability of no Fed cuts with hawkish risk rising 1.2 percentage points week-over-week
• MiniMed Flex launch is insufficient to reverse multi-year structural decline in Diabetes segment losing share to Dexcom, Abbott, and Tandem
• Zero MDT posts on Reddit in past week indicates no retail bid support; no marginal buyer to absorb institutional selling
• 24% rally from May low into upper Bollinger Band at $94.72 represents buying at top of range; adding into strength inverts basic risk management

→ vs aggressive: Aggressive proposal to add shares at $90-91 and again above $94.72 uses tighter stop ($3.64 cushion vs current $4.64) while increasing exposure, contradicting prudent risk management into a binary earnings event

→ vs aggressive: RSI at 59 with five sessions of lower highs and MACD declining from 2.64 peak is textbook topping pattern, not consolidation as characterized

→ vs aggressive: Forward P/E of 14.2x on 72% EPS growth assumption is vulnerable to derating if tax rate remains elevated at 31.4%; potential re-rating to 22-24x P/E with downside to $73-75

→ vs aggressive: Negative tangible book value with $52.73B in goodwill (57% of assets) creates structural impairment risk; common in industry doesn't mean inconsequential

→ vs aggressive: BofA upgrade creates higher bar for earnings; in-line delivery against elevated expectations causes disappointment-driven selling

→ vs aggressive: MiniMed Flex launch is single catalyst insufficient to reverse multi-year structural decline against established CGM competitors

→ vs aggressive: Dividend King narrative is sentimental marker, not structural re-rating event; stock needing sentiment support signals insufficient earnings strength

→ vs aggressive: Retail sentiment gap with zero Reddit posts means no marginal buyer to absorb institutional selling pressure

→ vs aggressive: Adding above $94.72 inverts risk management principle of taking profits into strength rather than adding into resistance

HOLD with refined parameters: core income allocation (not modest), stop at $87.75-$88.00, staged trims, add only on pullback to $89.50-$90.90, pre-earnings hold core without adding

• Forward P/E of 14x with 3.1% yield on 49-year dividend grower is not a stretched setup and Q4 FY26 operating leverage was real
• Technical setup shows momentum stalling: 5 sessions of lower highs after $94.72, MACD compressed from 2.64 to zero, candle closed below 10 EMA
• Negative tangible book value has existed for over a decade while MDT generated ~$8 billion annualized FCF, raised dividend every year, maintained investment grade credit
• Retail absence is irrelevant for a $116B mega-cap trading on institutional flows; not applicable to this name
• Position sizing should be core income allocation rather than modest—this changes how trims and adds are executed
• Stop loss should move to $87.75-$88.00, just below the 200 SMA, accepting tighter ATR cushion for structural integrity
• Trim trigger should be staged: 15-20% trim above $94, additional 10% on confirmed close above $96
• Add trigger is $89.50-$90.90 zone (20 SMA and VWMA confluence) on pullback, not at current levels or above resistance
• Q1 FY27 earnings success requires in-line to slightly-better print with credible tax guidance and MiniMed Flex commentary—blowout not needed
• Macro backdrop supportive but not without risk: 86% no-cut probability favors quality dividend payers, but hawkish risk ticked up 1.2 percentage points week-over-week

→ vs aggressive: Buying above $94.72 into a stalling setup at upper Bollinger Band after 24% rally is exactly how a good position becomes a problem; RSI at 59 doesn't justify ignoring the five sessions of lower highs and MACD compression that show buyers running out at resistance

→ vs conservative: BofA upgrade creating a 'higher bar' is technically correct but practically misleading for a 14x forward P/E defensive compounder—the bar isn't high in absolute terms and in-line print with positive guidance would likely support the stock

→ vs conservative: Negative tangible book value has been true for over a decade while the company raised dividends every year and generated ~$8 billion annualized FCF; treating this as imminent impairment overstates the risk when the actual evidence shows remarkable business model durability